5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes (DiViNe)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations ...
Voir le projet
6
Participants partenaires
TERMINÉ
Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial (HepaMAb)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
Worldwide, 200 million people are infected with the hepatitis C virus (HCV). An estimated 15 million individuals are living with HCV infection within the EU. The economic, health and societal costs of chronic HCV infection are significant. HCV is the principal cause of death from liver disease and the leading indication for liver transplantation. The only treatment for end-stage liver disease is a ...
Voir le projet
7
Participants partenaires
TERMINÉ
Scaffolds for alternative delivery (SADEL)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will progress through routes not travelled by antibodies while interacting with targets not modulated by chemical compounds.Existing Nf hits against validated targets will progre ...
Voir le projet
10
Participants partenaires
TERMINÉ
"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Voir le projet
12
Participants partenaires
TERMINÉ
NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BrainCAV)
Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,
Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique ...
Voir le projet